Vita Life Sciences Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Vita Life Sciences.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	47.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Vita Life Sciences no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

ASX:VLS - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	79	9	10	11	N/A
3/31/2024	77	9	11	12	N/A
12/31/2023	74	9	12	13	N/A
9/30/2023	71	8	10	10	N/A
6/30/2023	69	7	7	7	N/A
3/31/2023	68	7	5	5	N/A
12/31/2022	67	7	3	3	N/A
9/30/2022	65	8	2	2	N/A
6/30/2022	64	8	1	2	N/A
3/31/2022	61	8	4	4	N/A
12/31/2021	57	8	6	6	N/A
9/30/2021	54	8	6	6	N/A
6/30/2021	50	7	7	7	N/A
3/31/2021	48	6	7	7	N/A
12/31/2020	46	6	7	8	N/A
9/30/2020	46	6	7	7	N/A
6/30/2020	45	5	7	7	N/A
3/31/2020	44	4	5	5	N/A
12/31/2019	42	3	2	2	N/A
9/30/2019	42	2	2	2	N/A
6/30/2019	41	2	2	2	N/A
3/31/2019	41	2	3	3	N/A
12/31/2018	41	2	4	4	N/A
9/30/2018	40	3	N/A	N/A	N/A
6/30/2018	40	4	4	5	N/A
3/31/2018	38	3	N/A	4	N/A
12/31/2017	37	3	N/A	3	N/A
9/30/2017	37	3	N/A	N/A	N/A
6/30/2017	37	3	N/A	4	N/A
3/31/2017	38	3	N/A	5	N/A
12/31/2016	38	3	N/A	5	N/A
9/30/2016	38	4	N/A	4	N/A
6/30/2016	38	5	N/A	3	N/A
3/31/2016	39	5	N/A	4	N/A
12/31/2015	39	4	N/A	5	N/A
9/30/2015	38	4	N/A	6	N/A
6/30/2015	37	4	N/A	6	N/A
3/31/2015	37	6	N/A	6	N/A
12/31/2014	37	7	N/A	6	N/A
9/30/2014	36	7	N/A	6	N/A
6/30/2014	36	7	N/A	5	N/A
3/31/2014	36	6	N/A	5	N/A
12/31/2013	35	5	N/A	5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de VLS es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de VLS crezcan más rápidamente que el mercado Australian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de VLS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de VLS crezcan más rápidamente que el mercado de Australian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de VLS crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VLS se prevé que sea elevada dentro de 3 años.

Vita Life Sciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Recent updates

New minor risk - Shareholder dilution

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Now 22% undervalued

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Upcoming Dividend of AU$0.015 Per Share

New 90-day high - AU$0.95

First half earnings released

New 90-day high - AU$0.70

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento